Nuformix (FRA:1RT) Total Liabilities: €0.26 Mil (As of Mar. 2026)


What is Nuformix Total Liabilities?

Nuformix FRA:1RT Total Liabilities is €0.26 Mil as of Mar. 2026. The stock has 1 warning sign investors should review.

Nuformix's Total Liabilities for the quarter that ended in Mar. 2026 was €0.26 Mil.

Nuformix's quarterly Total Liabilities increased from Mar. 2025 (€0.28 Mil) to Sep. 2025 (€0.30 Mil) but then declined from Sep. 2025 (€0.30 Mil) to Mar. 2026 (€0.26 Mil).

Nuformix's annual Total Liabilities declined from Mar. 2023 (€0.31 Mil) to Sep. 2024 (€0.30 Mil) but then stayed the same from Sep. 2024 (€0.30 Mil) to Sep. 2025 (€0.30 Mil).

Nuformix Total Liabilities Historical Data

* Premium members only.

The historical data trend for Nuformix's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nuformix Total Liabilities Chart

Nuformix Annual Data
Trend Dec15 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Sep24 Sep25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.38 0.29 0.31 0.30 0.30

Nuformix Semi-Annual Data
Dec15 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.30 0.28 0.30 0.26

Nuformix Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Nuformix's Total Liabilities for the fiscal year that ended in Sep. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.304+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.30

Total Liabilities=Total Assets (A: Sep. 2025 )-Total Equity (A: Sep. 2025 )
=1.173-0.869
=0.30

Nuformix's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.262+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.26

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=2.15-1.887
=0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €0.26 Mil mean?
Nuformix (FRA:1RT) has a Total Liabilities of €0.26 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Nuformix and its competitors.
Is Nuformix's Total Liabilities too high?
Nuformix's current Total Liabilities is €0.26 Mil.
How does Nuformix's Total Liabilities compare to VRTX and REGN?
Nuformix's Total Liabilities of €0.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Nuformix and its competitors. Nuformix's current Total Liabilities is €0.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuformix stock overvalued right now?
Nuformix (FRA:1RT) has a current Total Liabilities of €0.26 Mil. The current Total Liabilities is €0.26 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Nuformix (FRA:1RT), the current Total Liabilities is €0.26 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nuformix Business Description

Other Exchanges NFX:UK1RT:Germany
Address C/O Arch Law Limited, 8 Bishopsgate, Huckletree Bishopsgate, London, GBR, EC2N 4BQ
Nuformix PLC is a pharmaceutical development company. It operates in pharmaceutical development, targeting unmet medical needs in fibrosis and oncology through drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.